FindTrial
Sign In

Observational Study of Levosimendan on Success Rate of Weaning and Prognosis in Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Patients

Observational Study of Levosimendan on Success Rate of Weaning and Prognosis in Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051905
Enrollment
Unknown
Registered
2021-10-09
Start date
2021-10-09
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart-derived shock

Interventions

The levosimendan group:None
No levosimendan group:None

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with VA-ECMO who were admitted to the multi-center ICU unit from January 2012 to October 2021.

Exclusion criteria

Exclusion criteria: 1.VA-ECMO duration < 2 days; 2.Patients who give up treatment midway due to the patient's own reasons; 3.Patients with liver failure; 4.Patients with malignant tumor.

Design outcomes

Primary

MeasureTime frame
Whether extracorporeal membrane oxygenation was successfully removed;30 Day generation rate;Cardiac ejection fraction;—

Countries

China

Contacts

Public ContactYe Lin

The First Affiliated Hospital of Chongqing Medical University

329464286@qq.com+86 13983118768

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026